Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 14612527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.

  2002cited by this paper
• ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

  2002cited by this paper
• Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.

  2002cited by this paper
• Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.

  2001cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Tumor angiogenesis as a therapeutic target.

  2001cited by this paper
• Technology evaluation: IMC-1C11, ImClone Systems.

  2001cited by this paper
• Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth

  2001cited by this paper
• Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.

  2001cited by this paper
• Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.

  2000cited by this paper
• PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

  2000cited by this paper
• Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.

  2000cited by this paper
• Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers

  2000cited by this paper
• ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

  2000cited by this paper
• Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

  2000cited by this paper
• VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

  1999cited by this paper
• Molecular and biological properties of vascular endothelial growth factor

  1999cited by this paper
• Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody

  1999cited by this paper
• mAngiogenin-3, a target gene of oncoprotein E2a-Pbx1, encodes a new angiogenic member of the angiogenin family.

  1999cited by this paper
• Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

  1997cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• Neovasculature induced by vascular endothelial growth factor is fenestrated.

  1997cited by this paper
• A model of angiogenesis in the mouse cornea.

  1996cited by this paper
• Expression of Growth Factors and Growth Factor Receptors in Capillary Hemangioblastoma

  1996cited by this paper
• Regulation of flt‐1 expression during mouse embryogenesis suggests a role in the establishment of vascular endothelium

  1996cited by this paper
• Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis.

  1995cited by this paper
• Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.

  1995cited by this paper
• Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper
• Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.

  1994cited by this paper
• Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation.

  1994cited by this paper
• flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors.

  1993cited by this paper
• Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells.

  1993cited by this paper
• Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium.

  1993cited by this paper
• The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.

  1992cited by this paper
• Molecular and biological properties of the vascular endothelial growth factor family of proteins.

  1992cited by this paper
• Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries.

  1990cited by this paper
• Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

  1989cited by this paper
• Angiogenesis: Mechanisms and Pathobiology

  1987cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper
• Basic Fibroblast Growth Factor Stimulates Endothelial Regrowth and Proliferation in Denuded Arteries

  year unknowncited by this paper

• Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family in GtoPdb v.2025.3

  2025cites this paper
• One-Year Ultralong Intravitreal Release of Tyrosine Kinase Inhibitor from Supramolecular Temperature-Responsive Hydrogel

  2025cites this paper
• Can Sustained Suppression of VEGF be Achieved by Topical Ocular Delivery?

  2025cites this paper
• Drug-like properties of tyrosine kinase inhibitors in ophthalmology: Formulation and topical availability.

  2024cites this paper
• Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties.

  2024cites this paper
• Challenges and opportunities of developing small-molecule therapies for age-related macular degeneration

  2024cites this paper
• In silico studies of a novel scaffold of benzoxazole derivatives as anticancer agents by 3D-QSAR, molecular docking and molecular dynamics simulations

  2023cites this paper
• A review of emerging tyrosine kinase inhibitors as durable treatment of neovascular age-related macular degeneration

  2023cites this paper
• Nickel(II) and cobalt(II) complexes with 4,5-dichloro-isothiazole-3-carboxylic acid and 1,10-phenanthroline: synthesis, crystal structures and cytotoxicity

  2022cites this paper
• Novel therapies for proliferative retinopathies

  2022cites this paper
• Limiting angiogenesis to modulate scar formation.

  2019cites this paper
• A Review on Isothiazoles and their Derivatives: Synthesis, Reactions and Pharmaceutical Importance

  2019cites this paper
• Isothiazoles in the Design and Synthesis of Biologically Active Substances and Ligands for Metal Complexes

  2019cites this paper
• The N’-Substituted Derivatives of 5-Chloro-3-Methylisothiazole-4-Carboxylic Acid Hydrazide with Antiproliferative Activity

  2019cites this paper
• Design, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives.

  2019cites this paper
• Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

  2018cites this paper
• Molecular and functional characterization of the American cockroach, Periplaneta americana, Rab5: the first exopterygotan low molecular weight ovarian GTPase during oogenesis

  2018cites this paper
• Ureas: Applications in Drug Design.

  2017cites this paper
• In silico ADME/T and 3D QSAR analysis of KDR inhibitors

  2017cites this paper
• Synthesis of new ferrocene derivatives with a 4,5-dichloroisothiazole fragment

  2017cites this paper
• Therapeutic Agents That Inhibit Angiogenesis

  2017cites this paper
• Synthesis of functional derivatives of isothiazole and isoxazole basing on (5-arylizoxazol-3-yl)- and (4,5-dichloroisothiazol-3-yl)arylmethanol

  2016cites this paper
• Administration of Menadione, Vitamin K3, Ameliorates Off-Target Effects on Corneal Epithelial Wound Healing Due to Receptor Tyrosine Kinase Inhibition

  2016influential citation
• A combination of 2D similarity search, pharmacophore, and molecular docking techniques for the identification of vascular endothelial growth factor receptor-2 inhibitors

  2015cites this paper
• 3D-QSAR study of tetrahydro-3H-imidazo[4,5-c]pyridine derivatives as VEGFR-2 kinase inhibitors using various charge schemes

  2015cites this paper
• Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies

  2015cites this paper
• 3D-QSAR study of tetrahydro-3H-imidazo[4,5-c]pyridine derivatives as VEGFR-2 kinase inhibitors using various charge schemes

  2015cites this paper
• The synthesis of isoxazolyl- and isothiazolylcarbamides exhibiting antitumor activity

  2014cites this paper
• Isoxazol-3-yl(Isothiazol-3-yl)-1,2,4-Triazoles, Tetrazoles, and -1,3,4-Oxadiazoles: Synthesis, Palladium Complexes, and Catalytic Applications

  2014cites this paper
• Using deuterium in drug discovery: leaving the label in the drug.

  2014cites this paper
• One feature doesn't fit all: characterizing topological features of targets in signaling networks

  2014cites this paper
• Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF

  2013cites this paper
• Kinase Inhibitors in Cancer

  2013cites this paper
• 3D-QSAR Study on a Series of VEGFR-2 Kinase Inhibitors: 3-Pyrrole Substituted Indolin-2-Ones Compounds

  2013cites this paper
• Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice.

  2013cites this paper
• Synthesis of alkyl (4,5-Dichloroisothiazol-3-yl) ketones and some of their derivatives

  2013cites this paper
• Synthesis of functionally substituted isoxazole and isothiazole derivatives

  2013cites this paper
• Novel targets and derived small molecule inhibitors in multiple myeloma.

  2012cites this paper
• Microwave-assisted novel and efficient one-pot synthesis of fused steroidal and non-steroidal isothiazoles

  2012cites this paper
• Cytotoxic effects of chemotherapeutic drugs and heterocyclic compounds at application on the cells of primary culture of neuroepithelium tumors.

  2012cites this paper
• Modeling VEGFR kinase inhibition of aminopyrazolopyridine urea derivatives using topological and physicochemical descriptors: a quantitative structure activity analysis study

  2012cites this paper
• Regulation of Angiogenesis in Human Cancer via Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2)

  2012cites this paper
• Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]

  2012cites this paper
• Recent advances in antiangiogenic agents with VEGFR as target.

  2011cites this paper
• VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.

  2011cites this paper
• Asymmetric synthesis of isothiazoles through Cu catalysis: direct catalytic asymmetric conjugate addition of allyl cyanide to α,β-unsaturated thioamides.

  2011cites this paper
• Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy

  2011cites this paper
• Improving the Efficiency of Chemotherapeutic Drugs by the Action on Neuroepithelial Tumors

  2011cites this paper
• Pani: a novel algorithm for fast discovery of putative target nodes in signaling networks

  2011cites this paper
• Molecular structure, pKa, lipophilicity, solubility, absorption, polar surface area, and blood brain barrier penetration of some antiangiogenic agents

  2011cites this paper
• Advances in studies on vascular endothelial growth factor receptor and its small-molecule inhibitors

  2011cites this paper
• Kinase Inhibitors in Signal Transduction Therapy

  2011cites this paper
• Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.

  2011cites this paper
• Angiogenesis: an update and potential drug approaches (review).

  2010cites this paper
• Targeted Agents in Ovarian Cancer

  2010cites this paper
• 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.

  2010cites this paper
• Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.

  2010cites this paper
• Synthesis and structure-activity relationship of 6-arylureido-3-pyrrol-2-ylmethylideneindolin-2-one derivatives as potent receptor tyrosine kinase inhibitors.

  2010cites this paper
• Vascular endothelial growth factor receptor-2 in breast cancer.

  2010cites this paper
• Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.

  2010cites this paper
• Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.

  2009cites this paper
• Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.

  2009cites this paper
• Chapter 5.5 - Five-Membered Ring Systems: With N and S (Se) Atoms

  2009cites this paper
• Modeling of vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitory activity of 2-anilino-5-aryloxazoles using chemometric tools

  2009cites this paper
• Targeting expression of the catalytic domain of the kinase insert domain receptor (KDR) in the peroxisomes of Pichia pastoris.

  2009cites this paper
• Proteina quinasas como dianas farmacológicas

  2009cites this paper
• Synthesis of Novel Vanillin Derivatives Containing Isothiazole Moieties and its Synergistic Effect in Mixtures with Insecticides

  2009cites this paper
• Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

  2009cites this paper
• Modelling angiogenesis in inflammation

  2008cites this paper
• Targeting Angiogenesis in the Treatment of Lung Cancer

  2008cites this paper
• Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico‐pathological parameters

  2008cites this paper
• Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

  2008cites this paper
• Angiogenesis and Non Small Cell Lung Cancer

  2008cites this paper
• Activated STAT3 is a mediator and biomarker of VEGF endothelial activation

  2008cites this paper
• Metabolism of 5-Isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): Identification of an Unusual N-Acetylglucosamine Conjugate in the Cynomolgus Monkey

  2008cites this paper
• A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment

  2008cites this paper
• Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC)

  2008cites this paper
• Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.

  2008cites this paper
• Antiangiogenic therapy and surgical practice

  2008cites this paper
• Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.

  2008cites this paper
• TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.

  2008cites this paper
• Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

  2008cites this paper
• Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.

  2008cites this paper
• New VEGF antagonists as possible therapeutic agents in vascular disease

  2008cites this paper
• Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC).

  2008cites this paper
• Delta-like Ligand 4/Notch Pathway in Tumor Angiogenesis

  2008cites this paper
• Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.

  2008cites this paper
• Vascular Endothelial Growth Factor

  2008cites this paper
• Antiangiogenic therapy in nonsmall cell lung cancer

  2008cites this paper
• Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

  2008cites this paper
• Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.

  2007cites this paper
• Vascular endothelial growth factor (VEGF) inhibition--a critical review.

  2007cites this paper
• VEGF/VEGFR signalling as a target for inhibiting angiogenesis

  2007influential citation
• Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

  2007cites this paper
• Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies.

  2007cites this paper
• New approaches in angiogenic targeting for colorectal cancer.

  2007cites this paper
• 7.08 – Kinase Inhibitors for Cancer

  2007cites this paper
• Protein Kinases and Protein Phosphatases in Signal Transduction Pathways

  2007cites this paper
• A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

  2007cites this paper
• Antiangiogenic agents: an update on small molecule VEGFR inhibitors.

  2007cites this paper